• Cerebionics, founded 2024 by Norwegian engineer Agnessa Pedersen, builds a non-invasive EEG headset that translates brain intent into commands for drones and unmanned systems, per Tech.eu.
• The startup's only reported funding is a $200,000 raise from Project Europe and three undisclosed investors, reported by Signalbase in July 2025 — not confirmed by Cerebionics or by the September 2026 Tech.eu profile.
• Testing runs through Ukrainian military personnel, pointing to defense and unmanned-systems procurement as the likely first commercial channel rather than consumer or clinical BCI markets.
• Calibration takes roughly an hour per session in optimal conditions, and the full signal chain from acquisition to end-system execution still carries meaningful latency, per the founder's own account.
• The company holds multiple letters of intent but names no signed customer, defense contract, or follow-on investor as of the profile date.

Cerebionics is chasing a narrower problem than most brain-computer interface startups: not decoding thought, but decoding intent — the decision to act — and turning it into a command a drone or unmanned system can execute, without opening the skull to do it. The four-person, Norwegian-founded company, now headquartered in London, says it is building "a highway between the brain and the end system, but doing it non-invasively," founder Agnessa Pedersen told Tech.eu in a profile published September 24, 2026. The mechanism and the testing partner are confirmed by that reporting; the size and shape of the company's balance sheet are not.

A Portable EEG Headset, Not an Implant

Cerebionics' system uses non-invasive EEG electrodes worn externally to capture the brain's electrical activity, then decodes patterns tied to intent rather than requiring the fine motor signal that invasive implants read directly from cortical tissue, per Tech.eu. Pedersen, who built drawing robots as a teenager before studying cybernetics and robotics in an integrated master's program, founded the company in 2024 and went full-time roughly a year later. The tradeoff for skipping surgery is signal noise: calibration reportedly takes about an hour per session even in optimal conditions.

The Only Funding Figure on Record Is Small, and Unconfirmed by the Company

The lone dollar figure tied to Cerebionics is a $200,000 raise from Project Europe and three unnamed investors, reported by funding-data publisher Signalbase in July 2025 — more than a year before the Tech.eu profile anchoring this analysis. Neither that profile nor any Cerebionics-issued material confirms a round size, stage, or valuation; on this point Signalbase is a single source, and its investor names are confidential. Prospective partners evaluating the company should treat the capital base as reported, not verified, until Cerebionics or a named investor discloses terms.

Ukraine Is the Test Bed, Which Tells You Who the First Buyer Is

Pedersen has tested and refined the interface with Ukrainian military personnel, according to Tech.eu — a detail that matters more than the funding figure. Non-invasive BCI for drone and unmanned-system control has an obvious defense use case: operators whose hands and voice are already committed to other tasks. That the earliest real-world feedback loop runs through an active conflict zone, rather than a lab or clinical trial, points toward defense and unmanned-systems procurement as Cerebionics' most plausible first commercial channel — not the consumer or medical-assistive markets BCI coverage usually defaults to.

Multiple Letters of Intent, Zero Named Contracts

Cerebionics says it holds multiple letters of intent, per Tech.eu, but the September 2026 profile names no signed customer, defense contract, or follow-on investor. A letter of intent is a non-binding signal of interest, not revenue or committed capital — worth noting, not dismissing, at a four-person company roughly two years old. The gap between letters of intent and confirmed funding or named partners is the clearest measure of how early-stage Cerebionics still is, whatever the ambition of the pitch.

The Verdict

Cerebionics has a real, technically coherent pitch — non-invasive intent-decoding for machine control, validated against live military testers rather than a demo reel — and that is more substance than most BCI startups show this early. But the financial record is thin: one $200,000 raise, reported by a single funding-data outlet, that the company has not itself confirmed, and no named contracts to date. Read the technology claim as credible and the business claim as unproven until Cerebionics discloses its own numbers.